Abstract
The chemistry of nitrogen-containing heterocyclic compound pyrrole and pyrrolidine has been a versatile field of study for a long time for its diverse biological and medicinal importance. Biomolecules such as chlorophyll, hemoglobin, myoglobin, and cytochrome are naturally occurring metal complexes of pyrrole. These metal complexes play a vital role in a living system like photosynthesis, oxygen carrier, as well storage, and redox cycling reactions. Apart from this, many medicinal drugs are derived from either pyrrole, pyrrolidine, or by its fused analogs. This review mainly focuses on the therapeutic potential of pyrrole, pyrrolidine, and its fused analogs, more specifically anticancer, anti-inflammatory, antiviral, and antituberculosis. Further, this review summarizes more recent reports on the pyrrole, pyrrolidine analogs, and their biological potential.
Graphical Abstract
Similar content being viewed by others
Introduction
Heterocycles are cyclic compounds that have at least one different element than carbon, such as sulfur, oxygen, nitrogen [1]. These heterocycles have received considerable attention because of their biological and pharmacological significance [2,3,4,5]. One of the heterocycles, pyrrole, is not naturally derived, but its analogs present in co-factors and natural products such as vitamin B12, bile pigments: bilirubin and biliverdin [6, 7], and the porphyrins of heme, chlorophyll, chlorins, bacteriochlorins, and porphyrinogens [8,9,10,11]. Pyrrole-containing secondary metabolites such as makaluvamine M, ryanodine, rhazinilam, lamellarin, prodigiosin, myrmicarin, and sceptrinare also exhibit potential biological activity [12,13,14,15,16,17,18,19]. Apart from this, pyrrole and pyrrolidine analogs have diverse therapeutic applications like fungicides, antibiotics, anti-inflammatory drugs, cholesterol-reducing drugs, anti-tubercular, and antitumor agents [20,21,22,23,24,25]. These are also known to inhibit reverse transcriptase in case of human immune deficiency virus type 1 (HIV-1) and cellular DNA polymerases protein kinases [26, 27]. The combination of different pharmacophore in a pyrrole and pyrrolidine ring system has led to more active compounds [28,29,30,31,32].
Naturally occurring pyrrole and pyrrolidine analogs
In naturally occurring metal complexes heme (1) and chlorophyll (2), four pyrrole rings are linked together to form porphyrin and then coordinate with iron and magnesium to form respective metal complexes (Fig. 1) [33]. These heme groups, surrounding a globin group, produce a tetrahedral structure known as hemoglobin, an oxygen carrier in animals [34]. Unlike hemoglobin, biomolecule myoglobin traps oxygen within muscle cells for energy production required for muscles to contract [35]. An essential biomolecule, vitamin B12, porphyrin, and cobalt metal complex, forms through the stable metal–carbon bond and plays a vital for proper growth (3 a–d) [36]. Further, the bile pigments (4) are obtained by the decomposition of the porphyrins ring. Formation of this yellowish pigment takes place in spleen, reticulo endothelial cells of the liver, and bone marrow [37]. Another pyrrole analog is ageliferin (5a), produced by sponges. First isolated from the caribbean and then okinawan marine sponges have potential antibacterial properties [38]. Similarly, nargenicin (5b) is isolated from Nocardia argeninensis found to be more effective against gram-positive bacteria [39] (Fig. 2).
Naturally derived pyrrole analogs
Pyrrole analogs isolated from microorganism
Similarly, pyrrolidine analogs including nicotine (6a), scalusamide (6b), bgugaine (6c), D-ribitol (6d), and aegyleptolidine (6e) showing diverse biological activities have been derived from natural sources and microorganisms [40, 41] (Fig. 3).
Naturally derived Pyrrolidine analogs (6a-e)
Pyrrole and pyrrolidine drug candidates
Nitrogen-containing heterocycles have been known for their therapeutic potential. Among medicinal drugs, many are containing pyrrole and pyrrolidine moiety [42, 43]. Some of the drugs have pyrrole, pyrrolidine moieties are already available in market, and some are under clinical trials. The following are the pyrrole, pyrrolidine (saturated pyrrole) drug candidates.
Telaprevir (7)
Pyrrolidine (saturated pyrrole) analog; telaprevir is an antiviral drug, peptidomimetic used in combination therapy to treat chronic Hepatitis C Virus (HCV) infection. This drug inhibits NS3/4A, a serine protease encoded by HCV genotype 1 and SARS-CoV-2 3CL proteases. Also, this drug is used with pegylated interferon and ribavirin for clinical trials [44,45,46] (Fig. 4).
Pyrrole, pyrrolidine analogs as drug candidates-I
Ramipril (8)
Ramipril is a competitive inhibitor of ACE, angiotensin-converting enzyme (ACE), responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII) and regulates blood pressure. Ramipril is used to treat hypertension, congestive heart failure, and to control the death rate [47, 48] as shown in Fig. 5.
Pyrrole, pyrrolidine analogs as drug candidates-II
Tolmetin (9)
Tolmetin is also known as 1-methyl-5-p-toluoylpyrrole-2-acetic acid or tolectin and belongs to class of non-steroidal anti-inflammatory drug used for osteoarthritis, rheumatoid arthritis, and juvenile arthritis [49, 50].
Sunitinib (10)
FDA-approved anticancer drug sunitinib is a tyrosine kinase (RTK) inhibitor used for treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Because of this, sunitinib is an orally administered formulation that inhibits cellular signaling by targeting multiple RTKs such as rearranged during transfection (RET), colony-stimulating factor 1 receptor (CSF-1R), and fms-like tyrosine kinase 3 (flt3) [51, 52].
Glimepiride (11)
Organic compounds such as sulfonylureas are used as insulin secretagogues to control type 2 diabetes, thereby reducing blood glucose levels. Glimepiride, a pyrrole analog, second-generation sulfonylureas is used for type 2 diabetes mellitus (T2DM) [53, 54].
Atorvastatin (12)
Literature evidenced an enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, known to catalyze the conversion of HMG-CoA to mevalonic acid. This conversion involves compounds that play different roles in lipid metabolism and transport, cholesterol, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) production. Like other statin medications, atorvastatin, a lipid-lowering drug, is also known to inhibit the HMG-CoA reductase, thereby control the endogenous production of cholesterol in the liver, and reduce the risk of cardiovascular disease. Further, combination of atorvastatin and aspirin is used for SARS-CoV-2 infection [55,56,57].
Ombitasvir (13)
Due to significant advances in antiviral drugs, many pyrrolidines ring containing analogs are also reported for their potential inhibitory activity toward different viruses. Like telaprevir, ombitasvir, another antiviral medication, is used as a combination therapy to treat chronic Hepatitis C. This molecule inhibits, more specifically, NS5A, a protein essential for viral replication and virion manifestation. This analog also acts as a potent inhibitor of SARS-CoV-2 [58,59,60].
Phensuximide (14)
Phensuximide (Fig. 6), a succinimide analog, possesses antiepileptic and anticonvulsant properties. These orally active drugs produce depolarization-induced accumulation of cyclic adenosine monophosphate and cyclic guanosine monophosphate (cGMP) [61, 62].
Pyrrole, pyrrolidine analogs as drug candidates-III
Pibrentasvir (15)
Like ombitasvir, pibrentasvir is an anti-hepatitis C virus (HCV) drug and specifically inhibits NS5A that targets the viral RNA replication and virion assembly. Also, in combination with glecaprevir, an NS3/4A protease inhibitor was used for patients with therapeutic failure from other NS5A inhibitors [63, 64].
Fused pyrrole as drug candidate
As such pyrrole and pyrrolidine scaffold itself shows diverse pharmacological properties. However, to attain increased biological activities toward various diseases, many fused pyrrole and pyrrolidine analogs have been reported [65, 66]. Further, these medicinally potent fused analogs have been derived from synthetic routes and isolation [67,68,69,70]. Because of this, present review also focuses very potent fused pyrrole and pyrrolidine analogs.
Tropisetron (serotonin receptor antagonist) (16)
A serotonin receptor antagonist inhibits serotonin (5-HT) receptors that regulate many neurotransmitters such as gamma-aminobutyric acid (GABA), glutamate, dopamine, acetylcholine, and epinephrine or norepinephrine. These receptors modulate many hormones like oxytocin, prolactin, vasopressin, cortisol, and corticotropin. Serotonin receptors were also responsible for aggression, anxiety, memory, learning, nausea, mood, and sleep [71, 72]. Among such antagonists, tropisetron, a fused pyrrole, an indole analog blocks the action of serotonin at 5HT3 receptors, resulting in control of nausea and vomiting induced by chemotherapy and radiotherapy [73, 74].
Ketorolac (17)
Ketorolac (Fig. 7) is one more non-steroidal anti-inflammatory drug (NSAID) that belongs to this class. This drug is available as an oral tablet, injection, nasal spray, and eye solution. Due to its analgesic properties, this drug is used, for the treatment of rheumatoid arthritis, postoperative pain, osteoarthritis, menstrual disorders, and as well for spondylitis [75, 76].
Fused pyrrole analogs as drug candidates-I
Ruxolitinib (18)
FDA-approved kinase inhibitors like ruxolitinib are used for adult patients with bone marrow disorders. Reports suggest that ruxolitinib may use for patients suffering from an infection caused by covid-19. However, this drug is clinically not approved for the treatment of covid-19 disease [77, 78].
Vemurafenib (19)
Like ruxolitinib, vemurafenib also belongs to the class of competitive kinase inhibitor. Specifically, it is active against serine-threonine kinase (BRAF kinase) with mutant V600E. It binds to the ATP-binding domain of the mutant BRAF and thereby exerts its function. Further, this compound is more effective against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) [79,80,81].
Remdesivir (20)
Remdesivir (GS-5734) is chemically named as N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alanine (Fig. 8). This adenosine triphosphate analog exhibits broad antiviral activity against viral families such as Flaviviridae, Arenaviridae, Coronaviridae, Paramyxoviridae, Pneumoviridae, and Filoviridae. Apart from this, remdesivir is in conditional use for COVID-19 infection as recommended by the World Health Organization [82,83,84,85,86].
Fused pyrrole, pyrrolidine analogs as drug candidates-II
Physostigmine (21)
Physostigmine, also known as eserine, a cholinesterase inhibitor, applied topically to the conjunctiva, can cross the blood–brain barrier and acts against anticholinergic toxicity [87].
Carprofen (22)
Carprofen is one more pyrrole analog, non-steroidal anti-inflammatory drug (NSAID) used for arthritic symptoms. Previously, carprofen was used for the treatment of gastrointestinal pain and nausea. Later, it is banned due to its toxicity [88, 89].
Baricitinib (23)
Literature evidences that Janus kinases belong to the tyrosine protein kinase family. These kinases play a role in the proinflammatory pathway signaling related to autoimmune disorders such as rheumatoid arthritis. Baricitinib, also known as olumiant, is used for rheumatoid arthritis. This analog is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitors, which disrupt the activation of downstream signaling molecules and proinflammatory mediators [90, 91].
Asenapine (24)
Asenapine is a sublingual tablet used as an antipsychotic to treat patients with bipolar I disorder and schizophrenia [92].
Pemetrexed (25)
Pemetrexed is a chemotherapy drug sold under the brand name alimta used in combination with cisplatin for patients with malignant pleural mesothelioma and non-squamous non-small cell lung cancer [93, 94].
Ribociclib (26)
Ribociclib is a selective anticancer drug and acts as a cyclin-dependent kinase inhibitor (Fig. 9). This drug inhibits specifically cyclin-dependent kinase 4 and 6 (CDK4/6), a protein that enables cancer cells to grow and divide vigorously [95, 96].
Fused pyrrole analogs as drug candidates-III
Tofacitinib (27)
Tofacitinib is a small molecule used for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [97]. Also, it acts as a Janus kinase (JAK) inhibitor [98].
Ondasetron (28)
Ondansetron, one more serotonin 5-HT3 receptor antagonist, is used for cancer patients to avoid nausea and vomiting due to chemotherapy, radiation therapy, or surgery [99]. Further, it prevents inflammation of the gastrointestinal tract [100].
Indomethacin (29)
Indomethacin, a benzopyrrole analog, is a nonsteroidal anti-inflammatory drug. The mechanism of action for this drug involves the inhibition of cyclooxygenase, an enzyme responsible for the production of prostaglandins [101].
Biologically potential of pyrrole and pyrrolidine analogs
Pyrrole and pyrrolidine, being an important ring structure, have been found to possess a number of biological activities; this ring has a broad range of biologically active compounds, incorporated either as a substituent or with various substitutions on the ring itself. This review mainly covers recent reports on potential activities of pyrrole and pyrrolidine analogs such as anticancer, antituberculosis, antiviral, and anti-inflammatory activity in comparison with earlier reviews that focus on the importance of pyrrole and its analogs until the year 2015–2019 [102,103,104].
Anticancer agents
Epigenetic modification refers to changes that alter the physical structure of DNA. Epigenetic modification involves both DNA methylation and histone modification [105, 106]. These two phenomena play vital role in the regulation of pluripotency genes. Based on the evidence, it has been suggested that most epigenetic therapies for cancer focus modulation of chromatin structure [107, 108]. One such therapy is based on the development of HDAC inhibitors. In view of this, Chen et al. [109] recently reported HDAC/BRD4 dual inhibitors as epigenetic probes. On the basis of structural activity relationship studies, they synthesized three potent pyrrolo-pyridine analogs (30 a–c) as dual inhibitors of HDAC1/BRD4 (Fig. 10).
Fused pyrrole analogs as potential anticancer agents I
Based on three-dimensional quantitative structure–activity relationship (3D-QSAR), molecular docking, and molecular dynamics (MD) simulations, Zhang et al. [110] reported target-specific anticancer agents. This investigation suggests that set of thieno[3,2-b]pyrrole (31), as competitive inhibitors of lysine-specific demethylase 1 (LSD1), a histone-modifying enzyme, is overexpressed in various cancers. Further, pyrrole/fused pyrrole analogs have to be explored for target specific anticancer activity [111, 112]. Rasal et al. [113] reported synthesis and antiproliferative activity of series of pyrrole bearing benzimidazole analogs. Among these compounds, only compound (32) showed significant antiproliferative activity in MDA-MB human cancer cell lines. Many natural products are known to possess potential anticancer activity [114, 115]. One such natural product, pyrrolomycin, a polyhalogenated antibiotic (33 a), has potent anticancer activity. However, this molecule is associated with high cytotoxicity. To overcome this problem, Raimondi et al. [116] designed and synthesized new pyrrolomycins (34 a–c). Their report suggested that newly synthesized compounds with nitro substituent strongly inhibit the proliferation of colon (HCT116) and breast (MCF 7) cancer cell lines in comparison with (33 a). Also, these molecules exhibit good antibacterial activity. Ji et al. [117] reported ruthenium-catalyzed synthesis and antiproliferation activities of poly substituted pyrrolidines. Among these analogs, only compounds (35 a, b) have shown strong antiproliferation activity with IC50—2.9 to 16 μM (Fig. 11).
Pyrrole, pyrrolidine analogs as potential anticancer agents-II
Investigation reveals that epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) downstream signaling pathways contribute to the tumor growth and progression. So, VEGF and EGFR inhibitors constitute therapies that inhibit different signaling pathways to overcome tumor resistance caused by the inhibition of a single. Because of this, Kuznietsova et al. [118] reported the synthesis of novel pyrrole analogs as protein kinases inhibitors. Their investigation suggested that two compounds, namely chloro-1-(4-chlorobenzyl)-4-((3-(trifluoromethyl)phenyl)amino)-1H-pyrrole-2,5-dione (36 a) and 5-amino-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1,2-dihydro-3H-pyrrole-3-one (36 b), are the competitive inhibitors of EGFR and VEGFR (Fig. 12).
Pyrrole (fused), pyrrolidine analogs as potential anticancer agents-III
Liu et al. [119] mentioned in their work synthesis and antiproliferative activity of 1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)-2-phenylethan-1-one as Akt inhibitors. Further, only compounds 37a and 37b showed high potency against all Akt isoforms. Dagar et al. [120] reported the one-pot synthesis of 3,4-diacylpyrrolo[1,2-a]pyrazine by the reaction of an α-haloketone, azide, and N-substituted pyrrole-2-carboxaldehyde. This investigation reveals that only compound (38) showed potential in vitro anticancer activity against oral adenosquamous carcinoma and triple-negative human breast cancer cells in comparison with standard capecitabine.
Olszewska et al. [121] reported the synthesis and anticancer activity of trifluoromethyl 2-phosphonopyrrole against denocarcinomic human alveolar basal epithelial cells (A549) and breast cancer cell line (MCF-7 cells). This study explains pyrrole analog (39) with trifluoro, phosphonyl, and phenyl group significantly inhibits cell cycle arrest at G1 and induces apoptosis in these cell line with IC50 36.5 μM ± 1.80 and 27.9 μM ± 1.68. Recently, Rathinaraj et al. [122] reported synthesis of nanoconjugates derived from folate gold bilirubin. Further, these nanoconjugates induce apoptosis in multidrug-resistant oral carcinoma cells. More recently, Xiang et al. [123] investigated the synthesis of bioavailable, potent pyrrolo[2,1-f][1,2,4]triazines as anticancer agent. The compound (40) showed PI3K alpha inhibition in human cancer cells with IC50 of 5.9 nM. Zhang et al. [124] reported one pot synthesis of pyrrole-imidazole analogs. Their work demonstrated that compound (41) has very potential inhibition for the two human pancreatic cancer cell lines such as PANC and ASPC-1. Furthermore, Geretto et al. [125] research on anticancer cancer activity of meso-(p-acetamidophenyl)-calix[4]pyrrole analog suggests that this compound (42) can cross the blood–brain barrier, forms DNA adduct and exhibits significant anticancer activity (Fig. 13).
Pyrrole (fused) analogs as potential anticancer agents-IV
Anti-inflammatory agents
Anti-inflammatory agents are the substances that reduce inflammation in the body caused due to the response of vascular tissues to damaged cells, pathogens, or irritants. These compounds prevent this response from the body that causes inflammation.
Further, anti-inflammatory agents are used for the prevention and treatment of cancer [126, 127]. Based on this importance, Said Fatahala et al. reported synthesis of pyrrolopyridine and pyrrolopyridopyrimidine analogs as anti-inflammatory agents. Their findings reveals that only the fused pyrroles, pyrrolopyridines (43, 44) (Fig. 14) showed good anti-inflammatory activity. Also, molecular docking study shows binding of these analogs with COX-2 [128]. Redzicka et al. [129] research work is based on design, synthesis, molecular docking simulations, and anti-inflammatory activity of series of pyrrolo[3,4-c]pyrrole. According to the results, compounds (45–47) have shown strong activity toward COX-1 and COX-2. Furthermore, single-crystal X-ray diffraction was recorded for (48). Xue et al. [130] reported the isolation of two nucleosides (49, 50) and two pyrrole analogs (51, 52) (Fig. 15) from Cordyceps militaris shown no significant activity against LPS-induced NO production in macrophage-like, Abelson leukemia virus-transformed cell line derived from BALB/c mice (RAW 264.7 cells).
Fused pyrrole analogs as potential anti-inflammatory agents-I
Pyrrole and imdiazole analogs as weak anti-inflammatory agents-II
Guan reported the isolation of pyrrol-2-aldehyde analogs such as jiangrine G (53), jiangrine A (54), and pyrrolezanthine (55) from the fermentation broth of Jiangella alba and Maytenus austroyunnanensis. Their results based on western blot analysis reveals that all three compounds modulate pro-inflammatory cytokines via MAPK p38 and NF-κB signaling pathways. Also, compounds (53) and (54) inhibit the expression of iNOS in LPS-induced RAW 264.7 cells [131]. Reale et al. [132] reported synthesis and anti-inflammatory activity of novel series of 1,5-diarylpyrrol-3-sulfur analogs. Further, molecular modeling studies suggest compound (56) (Fig. 16) has potential binding with COX-2 enzyme and showed a significant in vivo anti-inflammatory activity.
Pyrrole analogs as potential anti-inflammatory agents-III
With the continuation of their work on pyrrolo[3,4-d]pyridazinone, Szczukowski et al. [133] recently reported synthesis and anti-inflammatory activity of novel pyrrolo[3,4-d]pyridazinone analogs bearing 4-aryl-1-(1-oxoethyl)piperazine. Among synthesized compounds, 57 (a, b) and 58 (a, b) inhibit cyclooxygenase, have better affinity to COX-2 isoenzyme, and thereby exert promising anti-inflammatory and anti-oxidant activity (Fig. 17).
Fused pyrrole analogs as potential anti-inflammatory agents-IV
Maharjan et al. [134] reported isolation of nine compounds including quinones, fusarubin, ( +)-solaniol, javanicin, 9-desmethylherbarine, and pyrrole analogs; isomers of lucilactaene (59, 60, 61), (62), and (63) from roots of Scutellariae baicalensis. These isolated compounds showed potential anti-inflammatory activity by inhibiting NO production and pro-inflammatory cytokines in LPS-induced RAW 264.7 macrophage cells.
Mohd Faudzi et al. [135] reported synthesis of twenty-four chalcones of pyrroles as anti-inflammatory agents against nitric oxide (NO) and prostaglandin E2 (PGE2) controls IFN-γ/LPS-induced RAW 264.7 macrophage cells. Further, these results are supported by the crystal structure and molecular studies (64) (Fig. 18).
Pyrrole, pyrrolidine analogs as potential anti-inflammatory agents-V
More recently, Redzicka et al. [136] reported design, synthesis, and anti-inflammatory activity of N-substituted 3,4-pyrroledicarboximides (65 a–k), (66) and (67 a–d) (Fig. 19). All the synthesized compounds have shown inhibitory activity against COX-1 and COX-2 cyclooxygenase isoform and thereby exhibit potential activity. Also, this work is supported by QSAR study and X-ray diffraction studies.
Fused pyrrole analogs as potential anti-inflammatory agents-VI
Antiviral agents
Antiviral agents are known for their use in viral infections caused by HIV, herpes viruses, hepatitis B and C viruses, influenza A, B viruses, and SARS-CoV-2. A lot of research has been carried out for the development of antivirals and to study their mechanism toward pathogens. However, many antiviral agents have been restricted for their use. The main drawback of the antiviral drug is viruses use the host's cells to replicate. Today, the main difficulty associated with vaccines and antiviral drugs is viral variation and resistance. There will be a real challenge for the medicinal chemist to synthesize safe, specific, and effective antiviral drugs without harming the host [137,138,139,140]. In view of these findings, to find more potent antiviral agents, Tao et al. [141] recently studied effect of GS-441524 (68) (Fig. 20) and hydrolyzed product of remdesivir in Vero E6, Vero CCL-81, Calu-3, Caco-2 cells for anti-SARS-CoV-2 activity and anti-HCoV-OC43 activity in Huh-7 cells. Their investigation reveals that both remdesivir and GS-441524 have similar anti-SARS-CoV-2 potency in Vero cells, but higher in Calu-3 and Caco-2 cells, whereas in case of Huh-7 cells, remdesivir exhibits higher anti-HCoV-OC43 activity than GS-441524.
Pyrrole (fused) analogs as potential antiviral agents-I
Li et al. [142] more recently reported synthesis and antiviral activity of novel nucleoside analogues of pyrrolo-triazines. Their investigation reveals that 7-chloro-4-amino-pyrrolo[2,1-f][1,2,4]triazine (69 b) specifically inhibits human norovirus RNA-dependent RNA polymerase (RdRp), whereas compound 4-amino-pyrrolo[2,1-f][1,2,4]triazine (69 a) inhibits both murine and human norovirus RNA-dependent RNA polymerase (RdRp) in different cell lines. With the continuation of their work on pyrrole analog (70), a potent HIV inhibitor, Curreli reported a new and novel analog, NBD-14189 (71), with optimized antiviral activity against HIV-1, with IC50 of 89 nM. In addition, the in vitro ADME data suggest improvements in aqueous solubility and other properties of this compound compared to (70) [143]. Hawerkamp et al. [144] reported antiviral activity of tofacitinib, a kind of novel Janus kinase (JAK) inhibitor in keratinocytes. This study reveals that tofacitinib reduces T cell activation and down regulates gene regulation.
Based on the importance of porphyrin and its metal complexes, Sengupta et al. [145] synthesized novel Zn (II) complexes of nitro porphyrin derivatives (72, 73) (Fig. 21) and carried out anticancer and antivira l activities. This metal complexes showed very good anticancer activity against human lung cancer cell-line A549 and improved antiviral activity against a HIV-1 and SIVmac.
Pyrrole analogs as potential antiviral agents-II
In the year 2020, Liu et al. [146] reported the synthesis of dihydopyrrolidines. These analogs were screened for anti-influenza activity. Among these analogs, (74 a–d) (Fig. 22) has shown potetinal activity against IAVs with IC50 ranges from 3.11 to 9.23 μM. This investigation further illustrates that these compounds suppress NDAPH oxidase, NOX1 in MDCK cells.
Pyrrole, purine analogs as potential antiviral agents-II
Like human alphaherpesvirus 2 (HHV-2), Caprine alpha herpesvirus 1 (CpHV-1) causes the genital disorder. Because of this, Lanave et al. [147] studied the antiviral efficacy of compound PHA767491, fused pyrrole (75) toward HSV-1 and HSV-2 in vitro and as well in the mouse model. Yao et al. [148] reported isolation and anti-hepatitis B virus activity of natural products delicatulines A (76) and B (77), an adenine analogs and pyrrole analog (78). Their study is based on n-BuOH extract of Selaginella delicatula. Further, none of these compounds and few known compounds have exhibited better anti-HBV activity. Based on colorimetric viral infection and qRT-PCR assays, Liu et al. [149] studied sodium copper chlorophyllin (79) as potential antiviral agent against infection caused by divergent EV-A71 and coxsackievirus-A16 (CV-A16). In addition, viral gastroenteritis has become serious concern for children caused by rotavirus, coxsackievirus, and adenovirus which are the most common viruses that cause gastroenteritis. Taking this into consideration, Mohamed et al. reported synthesis and antiviral activity of pyrrolo[2,3-d] pyrimidine and pyrrolo[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine analogs against gastroenteric viral infections. Screening of the new compounds for anti-viral activities against Rotavirus Wa strain and coxsackievirus B4 suggests that compounds (80 a–e), (81 a–c) and (82 a–c) (Fig. 23) exhibited significant antiviral activity [150].
Fused pyrrole analogs as potential antiviral agents-III
Another virus, the novel SARS-CoV-2 that causes coronavirus disease 2019 (COVID-19) results in an inevitable pandemic. Development of antiviral drug against SARS-CoV-2 is considered to be real challenge. Comprehensive literature of this virus reveals that the main protease (Mpro), a SARS-CoV-2 enzyme, is an attractive drug target that prevents viral replication and transcription. Because of this, Ianevski et al. reported screening of 136 antivirals against the SARS-CoV-2 infection in Vero-E6 cells. Their investigation suggests that among these antivirals, only compounds nelfinavir, salinomycin, amodiaquine, obatoclax (83) (pyrrole analog), a small molecule and a pan-inhibitor of Bcl-2 family proteins, emetine, and homoharringtonine (fused pyrrole) (84) exhibited anti-SARS-CoV-2 activity [151] as shown in Fig. 23.
To find a probe that targets the main protease, Rao et al. work based on molecular docking, dynamics simulation, and screening of small molecules investigated pyranonigrin A (85), a secondary fungal metabolite as potential inhibitor against the main protease (Mpro) expressed in SARS-CoV-2 virus [152].Lu et al. [153] more recently reported synthesis of protoporphyrins (86 a–e) as antiviral agent against series of viruses such as Lassa virus (LASV), Machupo virus (MACV), and SARS-CoV-2 and subtypes of influenza A viral strains. Their results show that these compounds are very significant antiviral with IC50 values ranged from 0.91 to 1.88 μM.
Fakhar et al. [154] report based on the structure-based pharmacophore modeling, virtual screening workflow, ADMET, and molecular dynamics simulations revealed that compound ABBV-744 (87) has a strong affinity (ΔGbind − 45.43 kcal/mol) to the main protease. Further, this study also considered the other two compounds (88, 89) as potential inhibitors of SARS-CoV-2. In the year 2021, by the experimental evidence, Varghese et al. [155] have proposed a combination of obatoclax and berberine as possible antiviral drugs for SARS-CoV-2 infection (Fig. 24).
Pyrrole (fused), pyrrolidine, quinone analogs as potential antiviral agents-IV
Antimycobacterial agents
Today, treatment for multidrug-resistant (MDR) tuberculosis (TB) has become a real challenge [156]. Tuberculosis is an infection caused by gram-positive bacteria mycobacterium tuberculosis. This disease is treated with first-line drugs like isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin [157]. Second-line drugs that have been reported are capreomycin, kanamycin, and amikacin [158]. Due to the multidrug-resistant developed by the mycobacterium, there is a need for a potent drug candidate that can suppress the growth of this pathogen [159, 160]. To develop antitubercular agent, Volynets et al. reported synthesis and antitubercular activity of novel isoniazid bearing pyrrole analogs. Compound 1-methyl-1H-pyrrol-2-ylmethylene)-hydrazide (90) (Fig. 25) has shown inhibitory activity toward isoniazid-resistant strain with IC50 of 0.14 μM [161]. Shiva Raju et al. [162] also reported 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole analogs as novel anti-tubercular agents. In the series of compounds, (91 a, b) has shown very good anti-tubercular activity against mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration of 0.78 µg/mL.
Pyrrole (fused) analogs as potential antimycobacterial agents-I
Liu et al. [163] used virtual high-throughput screening, in vitro assay, and synthesized 1-(2-chloro-6-fluorobenzyl)-2,5-dimethyl-4-((phenethylamino)methyl)-1H-pyrrole-3-carboxylate (92) as anti-tubercular agents that inhibit ClpP1P2 peptidase in M. tuberculosis. Many nitrogen-containing heterocyclic compounds were designed, synthesized, and screened for their biological activities [164, 165]. However, pyrrole and pyrrolidine analogs have been attracted more for their diverse pharmacological activities [166].
By finding these significances in the literature, Joshi et al. [167] reported the synthesis and antimycobacterial activity of novel pyrrolyl benzamide derivatives against M. tuberculosis H37Rv and enoyl-ACP reductase enzyme. Compounds (93a–e) have shown significant InhA inhibitory activity. Furthermore, Poce et al. [168] reported pyrrole analog (94) as potential inhibitor of mycobacteria. Their study is based on synthesis of pyrrole analog by the variations in hit compound (95).
More recently, Arumugam et al. [169] synthesized new spirooxindolopyrrolidine-embedded indandione for in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv. Their results suggest that chlorine-substituted indandione (96 a, b) displayed potential activity with MIC 0.78 μg/mL compared to ethambutol having MIC of 1.56 μg/mL as shown in Fig. 26.
Pyrrole (fused) analogs as potential antimycobacterial agents-II
Eng et al. [170] reported as synthesis of [3R,4R]-4-Hypoxanthin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine and [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine as potent inhibitors of hypoxanthine–guanine phosphoribosyltransferase (HGPRT) with Ki values of 60 nM. Krause et al. [171] reported synthesis and antimycobacterial activity of series of new 4-substituted picolinohydrazonamides. Among these compounds, (98) acts as antimycobacterial agent with MIC 0.4 μg/mL.
Based on the literature survey, it has been suggested that compared to pyrrole analogs, pyrrolidine scaffold will be having more preference to the drug design because of unrestricted conformation of the ring [172]. Further, pyrrolidine analog has privileged N − 1 position for substitutions which were present in US FDA-approved drugs [173]. We restricted this review on pyrrole, pyrrolidine, and its therapeutic potential for the aspects such as anticancer, anti-inflammatory, antiviral, and antimycobacterial activity. Other biological activities of this scaffold deserve special attention.
Conclusion
The literature evidenced five-membered nitrogen-containing pyrrole and pyrrolidine have been known for their extensive biological and pharmacological activities. Many biomolecules have possessed either pyrrole, pyrrolidine, or fused pyrrole. Using structure–activity relationship and molecular docking studies, pyrrole and pyrrolidine analogs have been designed, synthesized, and screened for diverse therapeutic activities. Based on the comprehensive literature on the importance of these molecules, this review mainly highlights recent reports on these versatile molecules for anti-cancer, anti-inflammatory, antiviral, and antitubercular activity. Also, this review focuses on the pyrrole, pyrrolidine, and fused pyrrole-containing drug candidates. This review will be a useful platform for innovative researchers to work on pyrrole analogs to overcome drug resistance and toxicity.
References
Mermer A, Keles T, Sirin Y (2021) Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: a review. Bioorg Chem 114:105076. https://doi.org/10.1016/j.bioorg.2021.105076
Salehian F, Nadri H, Jalili-Baleh L, Abbas Y-ML, Bukhari SN et al (2021) A review: biologically active 3,4-heterocycle-fused coumarins. Eur J Med Chem 212:113034. https://doi.org/10.1016/j.ejmech.2020.113034
Maheshwari KK, Bandyopadhyay D (2021) Heterocycles in the treatment of neglected tropical diseases. Curr Med Chem 28:472–495. https://doi.org/10.2174/0929867327666200219141652
Jeelan Basha N, Goudgaon NM (2021) A comprehensive review on pyrimidine analogs-versatile scaffold with medicinal and biological potential. J Mol Struct 1246:131168. https://doi.org/10.1016/j.molstruc.2021.131168
Matada BS, Pattanashettar R, Yernale NG (2021) A comprehensive review on the biological interest of quinoline and its derivatives. Bioorg Med Chem 32:115973. https://doi.org/10.1016/j.bmc.2020.115973
Osman D, Cooke A, Young TR, Deery E, Robinson NJ et al (2021) The requirement for cobalt in vitamin B12: a paradigm for protein metalation. Biochim Biophys Acta Mol Cell Res 1868:118896. https://doi.org/10.1016/j.bbamcr.2020
Santos ML, D’Ambrosio M, Rodrigo AP, Parola AJ, Costa PM (2021) A transcriptomic approach to the metabolism of tetrapyrrolic photosensitizers in a marine annelid. Molecules 26:3924. https://doi.org/10.3390/molecules26133924
Haines DD, Tosaki A (2020) Heme degradation in pathophysiology of and counter measures to inflammation-associated disease. Int J Mol Sci 21:9698. https://doi.org/10.3390/ijms21249698
Ritter M, Oetama VSP, Schulze D, Muetzlaff K, Meents AK et al (2020) Pyrrolic and dipyrrolic chlorophyll degradation products in plants and herbivores. Chemistry 26:6205–6213. https://doi.org/10.1002/chem.201905236
Dukh M, Tabaczynski WA, Seetharaman S, Ou Z, Kadish KM et al (2020) Meso- and β-pyrrole-linked chlorin-bacteriochlorin dyads for promoting far-red fret and singlet oxygen production. Chemistry 26:14996–15006. https://doi.org/10.1002/chem.202003042
Bonkovsky HL, Dixon N, Rudnick S (2019) Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs). Mol Genet Metab 128:213–218. https://doi.org/10.1016/j.ymgme.2019.03.002
Lin S, McCauley EP, Lorig-Roach N, Tenney K, Naphen CN et al (2017) Another look at pyrroloiminoquinone alkaloids-perspectives on their therapeutic potential from known structures and semisynthetic analogues. Mar Drugs 15:98. https://doi.org/10.3390/md15040098
Woll KA, Haji-Ghassemi O, Van Petegem F (2021) Pathological conformations of disease mutant ryanodine receptors revealed by cryo-EM. Nat Commun 12:807. https://doi.org/10.1038/s41467-021-21141-3
Sirindil F, Weibel J, Pale P, Blanc (2019) A Total synthesis of rhazinilam through gold-catalyzed cycloisomerization–sulfonyl migration and palladium-catalyzed suzuki–miyaura coupling of pyrrolyl sulfonates. Organic Lett 14:5542–5546. https://doi.org/10.1021/acs.orglett.9b01860
Pfaffenbach M, Gaich T (2017) The rhazinilam-leuconoxine-mersicarpine triad of monoterpenoid indole alkaloids. Alkaloids Chem Biol 77:1–84. https://doi.org/10.1016/bs.alkal.2016.07.001
Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S et al (2021) Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer Sci 112:1963–1974. https://doi.org/10.1111/cas.14839
Yip CH, Mahalingam S, Wan KL, Nathan S (2021) Prodigiosin inhibits bacterial growth and virulence factors as a potential physiological response to interspecies competition. PLoS One 16:e0253445. https://doi.org/10.1371/journal.pone.0253445
Snyder SA, Elsohly AM, Kontes F (2010) Synthetic and theoretical investigations of myrmicarin biosynthesis. Angew Chem Int Ed Engl 49:9693–9698. https://doi.org/10.1002/anie.201005825
Cipres A, O’Malley DP, Li K, Finlay D, Baran PS et al (2010) Sceptrin, a marine natural compound, inhibits cell motility in a variety of cancer cell lines. ACS Chem Biol 5:195–202. https://doi.org/10.1021/cb900240k
Vijay K, Devi TS, Sree KK, Elgorban AM, Kumar P et al (2020) In vitro screening and in silico prediction of antifungal metabolites from rhizobacterium Achromobacter kerstersii JKP9. Arch Microbiol 20:2855–2864. https://doi.org/10.1007/s00203-020-01982-0
Jiang L, Chee PL, Gao J, Gan CRR, Owh C et al (2021) A new potent antimicrobial metalloporphyrin. Chem Asian J 16:1007–1015. https://doi.org/10.1002/asia.202100053
Mroz RM, Lisowski P, Tycinska A, Bierla J, Trzeciak PZ et al (2015) Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. J Physiol Pharmacol 66:111–128
Bays H, McKenney J, Davidson M (2005) Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther 3:789–820. https://doi.org/10.1586/14779072.3.5.789
Cordeiro R, Kachroo M (2020) Synthesis and biological evaluation of anti-tubercular activity of schiff bases of 2-Amino thiazoles. Bioorg Med Chem Lett 30:127655. https://doi.org/10.1016/j.bmcl.2020.127655
Xiang HY, Chen JY, Huan XJ, Chen Y, Gao ZB et al (2021) Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors Bioorg. Med. Chem. Lett 31:127710. https://doi.org/10.1016/j.bmcl.2020.127710
Mendonça DA, Bakker M, Cruz-Oliveira C, Neves V, Jimenez MA et al (2021) Penetrating the blood-brain barrier with new peptide-porphyrin conjugates having anti-hiv activity. Bioconjug Chem 32:1067–1077. https://doi.org/10.1021/acs.bioconjchem
Krishnamurthy S, Yoda H, Hiraoka K, Inoue T, Lin J et al (2021) Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer. Cancer Sci 112:1141–1149. https://doi.org/10.1111/cas.14785
Cawrse BM, Robinson NM, Lee NC, Wilson GM, Seley-Radtke KL (2019) Structural and biological investigations for a series of n-5 substituted pyrrolo [3,2-d] pyrimidines as potential anti-cancer therapeutics. Molecules 24:2656. https://doi.org/10.3390/molecules24142656
Kiyotoki S, Nishikawa J, Sakaida I (2020) Efficacy of vonoprazan for helicobacter pylori eradication. Intern Med 59:153–161. https://doi.org/10.2169/internalmedicine.2521-18
Paik J, Deeks ED (2019) Tofacitinib: a review in psoriatic arthritis. Drugs 79:655–663. https://doi.org/10.1007/s40265-019-01091-3
Ahmad S, Alam O, Naim MJ, Shaquiquzzaman M, Alam MM et al (2018) Pyrrole: an insight into recent pharmacological advances with structure activity relationship. Eur J Med Chem 157:527–561. https://doi.org/10.1016/j.ejmech.2018.08.002
Leone Roberti Maggiore U, Valenzano Menada M, Venturini PL, Ferrero S (2013) The potential of sunitinib as a therapy in ovarian cancer. Expert Opin Investig Drugs 22:1671–1686. https://doi.org/10.1517/13543784.2013.841138
Sato MR, da Silva PB, de Souza RA, dos Santos KC, Chorilli M (2015) Recent advances in nanoparticle carriers for coordination complexes. Curr Top Med Chem 15:287–297. https://doi.org/10.2174/1568026615666150108145614
Wang Q, Zhang R, Lu M, You G, Wang Y et al (2017) Bioinspired polydopamine-coated hemoglobin as potential oxygen carrier with antioxidant properties. Biomacromolecules 18:1333–1341. https://doi.org/10.1021/acs.biomac.7b00077
Silverstein TP, Kirk SR, Meyer SC, Holman KL (2015) Myoglobin structure and function: a multiweek biochemistry laboratory project. Biochem Mol Biol Educ 43:181–188. https://doi.org/10.1002/bmb.20845
Yahn GB, Abato JE, Jadavji NM (2021) Role of vitamin B12 deficiency in ischemic stroke risk and outcome. Neural Regen Res 16:470–474. https://doi.org/10.4103/1673-5374.291381
Creeden JF, Gordon DM, Stec DE Jr, Hinds TD (2021) Bilirubin as a metabolic hormone: the physiological relevance of low levels. Am J Physiol Endocrinol Metab 320:E191–E207. https://doi.org/10.1152/ajpendo.00405.2020
Jiang W, Wang D, Wilson BAP, Kang U, Bokesch HR et al (2021) Agelasine Diterpenoids and Cbl-b inhibitory ageliferins from the coralline demosponge astrosclera willeyana. Mar Drugs 19:361. https://doi.org/10.3390/md19070361
Pidot SJ, Rizzacasa MA (2020) The nargenicin family of oxa-bridged macrolide antibiotics. Chemistry 26:2780–2792. https://doi.org/10.1002/chem.201904053
Liu XC, Lai D, Liu QZ, Liu QZ, Zhou L, Liu Q, Liu ZL (2016) Bioactivities of a new pyrrolidine alkaloid from the root barks of Orixa japonica. Molecules 21:1665. https://doi.org/10.3390/molecules21121665
Islam MT, Mubarak MS (2020) Pyrrolidine alkaloids and their promises in pharmacotherapy. Adv Tradit Med 20:13–22. https://doi.org/10.1007/s13596-019-00419-4
Lang DK, Kaur R, Arora R, Saini B, Arora S (2020) Nitrogen-containing heterocycles as anticancer agents: an overview. Anticancer Agents Med Chem 20:2150–2168. https://doi.org/10.2174/1871520620666200705214917
Crepeau AZ, Treiman DM (2010) Levetiracetam: a comprehensive review. Expert Rev Neurother 10:159–171. https://doi.org/10.1586/ern.10.5
de Wispelaere M, Du G, Donovan KA, Zhang T, Eleuteri NA et al (2019) Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat Commun 10:3468. https://doi.org/10.1038/s41467-019-11429-w
Pathak N, Chen YT, Hsu YC, Hsu NY, Kuo CJ et al (2021) Uncovering flexible active site conformations of sars-cov-2 3cl proteases through protease pharmacophore clusters and COVID-19 Drug Repurposing. ACS Nano 15:857–872. https://doi.org/10.1021/acsnano.0c07383
Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C et al (2019) Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 18:2229–2239. https://doi.org/10.3748/wjg.v25.i18.2229
Abouelkheir M (2021) Evaluation of dual inhibitory effect of anagliptin, ramipril, and lisinopril on angiotensin-converting enzyme and dpp-4 activities. Curr Mol Pharmacol. https://doi.org/10.2174/1874467214666210601104117
Erpolat OP, Senturk E, Saribas S, Pasinlioglu B, Gulbahar O et al (2021) Angiotensin-converting enzyme inhibitor reduces radiation-induced periprosthetic capsular fibrosis. J Surg Res 263:167–175. https://doi.org/10.1016/j.jss.2021.01.033
Ramadan AA, Elbakry AM, Esmaeil AH, Khaleel SA (2018) Pharmaceutical and pharmacokinetic evaluation of novel rectal mucoadhesive hydrogels containing tolmetin sodium. J Pharm Investig 48:673–683. https://doi.org/10.1007/s40005-017-0365-1
Akl MA, Ismael HR, Abd Allah FI, Kassem AA et al (2019) Tolmetin sodium-loaded thermosensitive mucoadhesive liquid suppositories for rectal delivery; strategy to overcome oral delivery drawbacks. Drug Dev Ind Pharm 45:252–264. https://doi.org/10.1080/03639045.2018.1534858
Tannir NM, Signoretti S, Choueiri TK, McDermott DF et al (2021) Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res 27:78–86. https://doi.org/10.1158/1078-0432.CCR-20-2063
Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W et al (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 77:441–464. https://doi.org/10.1007/s00228-020-03014-8
Fokoun C, Serrier H, Rabier H, Goutelle S, Tod M et al (2021) Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study. Pharmacogenomics J 21:559–565. https://doi.org/10.1038/s41397-021-00232-w
He B, Li X, Zhou Z (2021) Continuous spectrum of glucose dysmetabolism due to the KCNJ11 gene mutation-Case reports and review of the literature. J Diabetes 13:19–32. https://doi.org/10.1111/1753-0407.13114
Altwairgi AK, Alghareeb WA, AlNajjar FH, Alhussain H, Alsaeed E et al (2021) Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study. Invest New Drugs 39:226–231. https://doi.org/10.1007/s10637-020-00992-5
Ahmadi M, Mehdikhani M, Varshosaz J, Farsaei S, Torabi H (2021) Pharmaceutical evaluation of atorvastatin-loaded nanostructured lipid carriers incorporated into the gelatin/hyaluronic acid/polycaprolactone scaffold for the skin tissue engineering. J Biomater Appl 35:958–977. https://doi.org/10.1177/0885328220970760
Ghati N, Roy A, Bhatnagar S, Bhati S, Bhushan S et al (2020) Atorvastatin and aspirin as adjuvant therapy in patients with sars-cov-2 infection: a structured summary of a study protocol for a randomised controlled trial. Trials 21:902. https://doi.org/10.1186/s13063-020-04840-y
Ahmed M, Mansey AE, Wahsh EA, Gomaa AA, Rabea HM (2021) Efficacy and safety of ombitasvir plus paritaprevir, ritonavir and ribavirin in non-cirrhotic treatment-naïve and treatment-experienced egyptians with chronic HCV genotype-4 infection. Curr Med Sci 41:581–586. https://doi.org/10.1007/s11596-021-2363-9
Trifan Anca, Stanciu Carol, Iliescu Laura, Sporea Ioan, Baroiu Liliana et al (2021) Effectiveness of 8- and 12-Week treatment with ombitasvir/ paritaprevir/ritonavir and dasabuvir in treatment-naïve HCV patients in a real-life setting in Romania: the AMETHYST study. J Gastrointest Liver Dis 30(1):88–93. https://doi.org/10.15403/jgld-3373
Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, Fortin GM, Rayalam S, Taval S (2021) Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol 4:93. https://doi.org/10.1038/s42003-020-01577-x
Wang S, Meng X, Wang Y, Liu Y, Xia J (2019) HPO-Shuffle: an associated gene prioritization strategy and its application in drug repurposing for the treatment of canine epilepsy. Biosci Rep. https://doi.org/10.1042/BSR20191247
Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (1979) Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy. Neurology 29:1509–1513. https://doi.org/10.1212/wnl.29.11.1509
Zhang Y, Jiang X, Zhao Y, Xu Y (2021) Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: a meta-analysis. J Viral Hepat 28:177–185. https://doi.org/10.1111/jvh.13409
Aghemo A, Horsmans Y, Bourgeois S, Bondin M, Gschwantler M et al (2021) Real-world outcomes in historically underserved patients with chronic hepatitis c infection treated with glecaprevir/pibrentasvir. Infect Dis Ther. https://doi.org/10.1007/s40121-021-00455-1
Wojcicka A, Redzicka A (2021) An overview of the biological activity of pyrrolo[3,4-c]pyridine derivatives. Pharmaceuticals 14:354. https://doi.org/10.3390/ph14040354
Fukuda T, Ishibashi F, Iwao M (2020) Lamellarin alkaloids: isolation, synthesis, and biological activity. Alkaloids Chem Biol 83:1–112. https://doi.org/10.1016/bs.alkal.2019.10.001
Wang S, Wang S, Song S, Gao Q, Wen C et al (2021) Modular and stereoselective approach to highly substituted indole/pyrrole-fused diazepanones. J Org Chem 86:6458–6466. https://doi.org/10.1021/acs.joc.1c00303
Hong FL, Chen YB, Ye SH, Zhu GY, Zhu XQ et al (2020) Copper-catalyzed asymmetric reaction of alkenyl diynes with styrenes by formal [3 + 2] cycloaddition via cu-containing all-carbon 1,3-dipoles: access to chiral pyrrole-fused bridged [2.2.1] skeletons. J Am Chem Soc 142:7618–7626. https://doi.org/10.1021/jacs.0c01918
Mathada BS, Yernale NG, Basha JN, Badiger J (2021) An insight into the advanced synthetic recipes to access ubiquitous indole heterocycles. Tetrahedron Lett 85:153458. https://doi.org/10.1016/j.tetlet.2021.153458
Al-Matarneh MC, Amarandi RM, Mangalagiu II, Danac R (2021) Synthesis and biological screening of new cyano-substituted pyrrole fused (iso)quinoline derivatives. Molecules 26:2066. https://doi.org/10.3390/molecules26072066
Alvarez BD, Morales CA, Amodeo DA (2021) Impact of specific serotonin receptor modulation on behavioral flexibility. Pharmacol Biochem Behav 24:73243. https://doi.org/10.1016/j.pbb.2021.173243
Gerbier R, Ndiaye-Lobry D, Martinez de Morentin PB, Cecon E et al (2021) Pharmacological evidence for transactivation within melatonin MT2 and serotonin 5-HT2C receptor heteromers in mouse brain. FASEB J 35:e21161. https://doi.org/10.1096/fj.202000305R
Polovinkin L, Hassaine G, Perot J, Neumann E, Jensen AA et al (2018) Conformational transitions of the serotonin 5-HT3 receptor. Nature 563:275–279. https://doi.org/10.1038/s41586-018-0672-3
Rivera-Fonseca JL, Gonzalez-Rivas N, Unnamatla MVB, Garcia-Eleno MA, Reyes H et al (2021) Synthesis and development of indole based 5-ht3 receptor antagonists as anti-emetic drugs in oncology: an update. Curr Med Chem. https://doi.org/10.2174/0929867328666210708091134
da Silva J, Gingras (2021) A usage analysis of ketorolac in the emergency department. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2020.07.029
Hutka B, Lazar B, Toth AS, Agg B, Laszlo SB et al (2021) The nonsteroidal anti-inflammatory drug ketorolac alters the small intestinal microbiota and bile acids without inducing intestinal damage or delaying peristalsis in the rat. Front Pharmacol 12:664177. https://doi.org/10.3389/fphar.2021
Tefferi A (2021) Primary myelofibrosis: update on diagnosis, risk-stratification and management. Am J Hematol 96:145–162. https://doi.org/10.1002/ajh.26050
Annucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L et al (2021) RUXO-COVID study group. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia 35:1121–1133. https://doi.org/10.1038/s41375-020-01018-y
Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R (2021) Systematic review of BRAF/MEK inhibitors-induced severe cutaneous adverse reactions (SCARs). J Eur Acad Dermatol Venereol 35:607–614. https://doi.org/10.1111/jdv.16894
Bourque MS, Salek M, Sabin ND, Canale M, Upadhyaya SA (2021) Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatr Blood Cancer 68:e28814. https://doi.org/10.1002/pbc.28814
Ianevski A, Yao R, Biza S, Zusinaite E, Mannik A et al (2020) Identification and tracking of antiviral drug combinations. Viruses 12:1178. https://doi.org/10.3390/v12101178
Lamb YN (2020) Remdesivir: first approval. Drugs 80:1355–1363. https://doi.org/10.1007/s40265-020-01378-w
Le MP, Le Hingrat Q, Jaquet P, Wicky PH, Bunel V et al (2020) Removal of remdesivir’s metabolite gs-441524 by hemodialysis in a double lung transplant recipient with COVID-19. Antimicrob Agents Chemother 64:e01521-20. https://doi.org/10.1128/AAC.01521-20
Manning TJ, Thomas-Richardson J, Cowan M, Beard T (2020) Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals. Drug Discov Today 25:956–958. https://doi.org/10.1016/j.drudis.2020.04.010
Wang Y, Zhang D, Du G, Du R, Zhao J et al (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9
Aleissa MM, Silverman EA, Paredes Acosta LM, Nutt CT, Richterman A et al (2020) New perspectives on antimicrobial agents: remdesivir treatment for COVID-19. Antimicrob Agents Chemother 65:e01814-20. https://doi.org/10.1128/AAC.01814-20
Wang GS, Baker K, Ng P, Janis GC, Leonard J et al (2021) A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clin Toxicol (Phila) 59:698–704. https://doi.org/10.1080/15563650.2020.1854281
Burch M-A, Keshishian A, Wittmann C, Nehrbass D, Styger U et al (2021) The non-steroidal anti-inflammatory drug carprofen negatively impacts new bone formation and antibiotic efficacy in a rat model of orthopaedic-device-related infection. Eur Cells and Mater 41:739–755. https://doi.org/10.22203/eCM.v041a47
Grzanna MW, Secor EJ, Fortuno LV, Au AY, Frondoza CG (2020) Anti-Inflammatory effect of carprofen is enhanced by avocado/soybean unsaponifiables, glucosamine and chondroitin sulfate combination in chondrocyte microcarrier spinner culture. Cartilage 11:108–116. https://doi.org/10.1177/1947603518783495
El Jammal T, Seve P, Gerfaud-Valentin M, Jamilloux Y (2021) State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis. Expert Opin Pharmacother 22:205–218. https://doi.org/10.1080/14656566.2020.1822325
Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE et al (2021) Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 184:460–475. https://doi.org/10.1016/j.cell.2020.11.007
Vieta E, Montes JM (2018) A review of asenapine in the treatment of bipolar disorder. Clin Drug Investig 38:87–99. https://doi.org/10.1007/s40261-017-0592-2
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR et al (2017) AURA3 Investigators. osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640. https://doi.org/10.1056/NEJMoa1612674
Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T et al (2020) Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer. J Clin Oncol 38:2187–2196. https://doi.org/10.1200/JCO.19.02674
Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F (2021) Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, Breast. Cancer Res Treat 86:219–227. https://doi.org/10.1007/s10549-020-06001-w
Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW et al (2021) Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs 81:317–331. https://doi.org/10.1007/s40265-020-01461-2
Alvaro-Gracia JM, Garcia-Llorente JF, Valderrama M, Gomez S, Montoro M (2020) Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review. Rheumatol Ther 18:17–40. https://doi.org/10.1007/s40744-020-00258-9
Lopez-Sanroman A, Esplugues JV, Domenech E (2021) Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol 44:39–48. https://doi.org/10.1016/j.gastrohep.2020.04.012
Wang R, Song X, Chen Y, Wang N, Wang J (2021) Comparison of ondansetron and tropisetron in preventing postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. Saudi Med J 42(7):707–713. https://doi.org/10.15537/smj.2021.42.7.20210135
Freedman SB, Williamson-Urquhart S, Heath A, Echlivanoglou P, Hopkin G et al (2020) Multi-dose oral ondansetron for pediatric gastroenteritis: study protocol for the multi-dose oral ondansetron for pediatric acute gastroenteritis (DOSE-AGE) pragmatic randomized controlled trial. Trials 21:435. https://doi.org/10.1186/s13063-020-04347-6
Pacifici GM (2013) Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure. Paediatr Drugs 15:363–376. https://doi.org/10.1007/s40272-013-0031-7
Gholap SS (2016) Pyrrole: an emerging scaffold for construction of valuable therapeutic agents. Eur J Med Chem 110:13–31. https://doi.org/10.1016/j.ejmech.2015.12.017
Dhillon S (2017) Tofacitinib: a Review in rheumatoid arthritis. Drugs 77:1987–2001. https://doi.org/10.1007/s40265-017-0835-9
Li Petri G, Spano V, Spatola R, Holl R, Raimondi MV et al (2020) Bioactive pyrrole-based compounds with target selectivity. Eur J Med Chem 208:112783. https://doi.org/10.1016/j.ejmech.2020.112783
Parry A, Rulands S, Reik W (2021) Active turnover of DNA methylation during cell fate decisions. Nat Rev Genet 22:59–66. https://doi.org/10.1038/s41576-020-00287-8
Chlamydas S, Papavassiliou AG, Piperi C (2021) Epigenetic mechanisms regulating COVID-19 infection. Epigenetics 16:263–270. https://doi.org/10.1080/15592294.2020.1796896
Guha M, Srinivasan S, Guja K, Mejia E, Garcia-Diaz M et al (2016) HnRNPA2 is a novel histone acetyltransferase that mediates mitochondrial stress-induced nuclear gene expression. Cell Discov 2:16045. https://doi.org/10.1038/celldisc.2016.45
Modak R, Basha J, Bharathy N, Maity K, Mizar P et al (2013) Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor. ACS Chem Biol 8:1311–1323. https://doi.org/10.1021/cb4000597
Chen J, Li Y, Zhang J, Zhang M, Wei A et al (2021) Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes. Eur J Med Chem 209:112868. https://doi.org/10.1016/j.ejmech.2020.112868
Zhang X, Yan J, Wang H, Wang Y, Wang J et al (2021) Molecular docking, 3D-QSAR, and molecular dynamics simulations of thieno[3,2-b]pyrrole derivatives against anticancer targets of KDM1A/LSD1. J Biomol Struct Dyn 39:1189–1202. https://doi.org/10.1080/07391102.2020.1726819
Sugiura M, Sato H, Kanesaka M, Imamura Y, Sakamoto S et al (2021) Epigenetic modifications in prostate cancer. Int J Urol 28:140–149. https://doi.org/10.1111/iju.14406
Grady WM, Yu M, Markowitz SD (2021) Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer. Gastroenterology 160:690–709. https://doi.org/10.1053/j.gastro.2020.09.058
Rasal NK, Sonawane RB, Jagtap SV (2020) Potential 2,4-dimethyl-1H-pyrrole-3-carboxamide bearing benzimidazole template: design, synthesis, in vitro anticancer and in silico ADME study. Bioorg Chem 97:103660. https://doi.org/10.1016/j.bioorg.2020.103660
Basha NJ, Basavarajaiah SM, Baskaran S, Kumar P (2021) A comprehensive insight on the biological potential of embelin and its derivatives. Nat Prod Res. https://doi.org/10.1080/14786419.2021.1955361
Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK et al (2014) Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer 13:66. https://doi.org/10.1186/1476-4598-13-66
Raimondi MV, Presentato A, Petri GL, Buttacavoli M, Ribaudo A et al (2020) New synthetic nitro-pyrrolomycins as promising antibacterial and anticancer agents. Antibiotics 9(6):292. https://doi.org/10.3390/antibiotics9060292
Ji J, Sajjad F, You Q, Xing D, Fan H et al (2020) Synthesis and biological evaluation of substituted pyrrolidines and pyrroles as potential anticancer agents. Arch Pharm (Weinheim) 353:e2000136. https://doi.org/10.1002/ardp.202000136
Kuznietsova H, Dziubenko N, Byelinska I, Hurmach V, Bychko A et al (2020) Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety. J Drug Target 28:547–563. https://doi.org/10.1080/1061186X.2019.1703189
Liu Y, Zhang Z, Ran F, Guo K, Chen X et al (2020) Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity. Bioorg Chem 97:103671. https://doi.org/10.1016/j.bioorg.2020.103671
Dagar A, Seo Y, Namkung W, Kim I (2020) A domino annulation approach to 3,4-diacylpyrrolo[1,2-a]pyrazines: decoration of pyrazine units. Org Biomol Chem 18:3324–3333. https://doi.org/10.1039/D0OB00444H
Olszewska P, Cal D, Zagorski P, Mikiciuk-Olasik E (2020) A novel trifluoromethyl 2-phosphonopyrrole analogue inhibits human cancer cell migration and growth by cell cycle arrest at G1 phase and apoptosis. Eur J Pharmacol 871:172943. https://doi.org/10.1016/j.ejphar.2020.172943
Rathinaraj P, Muthusamy G, Prasad NR, Gunaseelan S, Kim B et al (2020) Folate-gold-bilirubin nanoconjugate induces apoptotic death in multidrug-resistant oral carcinoma cells. Eur J Drug Metab Pharmacokinet 45:285–296. https://doi.org/10.1007/s13318-019-00600-9
Xiang HY, Wang X, Chen YH, Zhang X, Tan C et al (2021) Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. Eur J Med Chem 209:112913. https://doi.org/10.1016/j.ejmech.2020.112913
Zhang M, Ding Y, Qin HX, Xu ZG, Lan HT et al (2020) One-pot synthesis of substituted pyrrole-imidazole derivatives with anticancer activity. Mol Divers 24:1177–1184. https://doi.org/10.1007/s11030-019-09982-z
Geretto M, Ponassi M, Casale M, Pulliero A, Cafeo G et al (2018) A novel calix[4]pyrrole derivative as a potential anticancer agent that forms genotoxic adducts with DNA. Sci Rep 8:11075. https://doi.org/10.1038/s41598-018-29314-9
Dinarello CA (2010) Anti-inflammatory agents: present and future. Cell 140:935–950. https://doi.org/10.1016/j.cell.2010.02.043
Zappavigna S, Cossu AM, Grimaldi A, Bocchetti M, Ferraro GA et al (2020) Anti-Inflammatory drugs as anticancer agents. Int J Mol Sci 21:2605. https://doi.org/10.3390/ijms21072605
Said Fatahala S, Hasabelnaby S, Goudah A, Mahmoud GI, Helmy Abd-El Hameed R (2017) Pyrrole and fused pyrrole compounds with bioactivity against inflammatory mediators. Molecules 22:461. https://doi.org/10.3390/molecules22030461
Redzicka A, Szczukowski L, Kochel A, Wiatrak B, Gębczak K et al (2019) COX-1/COX-2 inhibition activities and molecular docking study of newly designed and synthesized pyrrolo[3,4-c]pyrrole Mannich bases. Bioorg Med Chem 27:3918–3928. https://doi.org/10.1016/j.bmc.2019.07.033
Xue Y, Wu L, Ding Y, Cui X, Han Z et al (2020) A new nucleoside and two new pyrrole alkaloid derivatives from Cordyceps militaris. Nat Prod Res 34:341–350. https://doi.org/10.1080/14786419.2018.1531861
Guan P, Wang X, Jiang Y, Dou N, Qu X et al (2020) The anti-inflammatory effects of jiangrines from Jiangella alba through inhibition of p38 and NF-κB signaling pathways. Bioorg Chem 95:103507. https://doi.org/10.1016/j.bioorg.2019.103507
Reale A, Brogi S, Chelini A, Paolino M, Di Capua A et al (2019) Synthesis, biological evaluation and molecular modeling of novel selective COX-2 inhibitors: sulfide, sulfoxide, and sulfone derivatives of 1,5-diarylpyrrol-3-substituted scaffold. Bioorg Med Chem 27:115045. https://doi.org/10.1016/j.bmc.2019.115045
Szczukowski L, Krzyzak E, Zborowska A, Zając P, Potyrak K et al (2020) Design, Synthesis and comprehensive investigations of pyrrolo[3,4-d]pyridazinone-based 1,3,4-oxadiazole as new class of selective cox-2 inhibitors. Int J Mol Sci 21:9623. https://doi.org/10.3390/ijms21249623
Maharjan S, Lee SB, Kim GJ, Cho SJ, Nam JW et al (2020) Isolation of unstable isomers of lucilactaene and evaluation of anti-inflammatory activity of secondary metabolites produced by the endophytic fungus Fusarium sp. Q F001 from the roots of Scutellaria baicalensis. Molecules 25:923. https://doi.org/10.3390/molecules25040923
Mohd Faudzi SM, Abdullah MA, Abdull Manap MR, Ismail AZ (2020) Inhibition of nitric oxide and prostaglandin E2 production by pyrrolylated-chalcones: synthesis, biological activity, crystal structure analysis, and molecular docking studies. Bioorg Chem 94:103376. https://doi.org/10.1016/j.bioorg.2019.103376
Redzicka A, Czyznikowska Z, Wiatrak B, Gębczak K, Kochel A (2021) Design and synthesis of n-substituted 3,4-pyrroledicarboximides as potential anti-inflammatory agents. Int J Mol Sci 22:1410. https://doi.org/10.3390/ijms22031410
Yang PL (2021) Antiviral therapeutics. ACS. Infect Dis 7:1297. https://doi.org/10.1021/acsinfecdis.1c00271
Adamson CS (2020) Antiviral agents: discovery to resistance. Viruses 12:406. https://doi.org/10.3390/v12040406
Zhao M, Zhang J, Li H, Luo Z, Ye J et al (2021) Recent progress of antiviral therapy for coronavirus disease 2019. Eur J Pharmacol 890:173646. https://doi.org/10.1016/j.ejphar.2020.173646
Santoro MG, Carafoli E (2021) Remdesivir: from Ebola to COVID-19. Biochem Biophys Res Commun 538:145–150. https://doi.org/10.1016/j.bbrc.2020.11.043
Tao S, Zandi K, Bassit L, Ong YT, Verma K et al (2021) Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. Current Res Pharmacol Drug Discovery 2:100045. https://doi.org/10.1016/j.crphar.2021.100045
Li Q, Groaz E, Rocha-Pereira J, Neyts J, Herdewijn P (2020) Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides. Eur J Med Chem 195:112198. https://doi.org/10.1016/j.ejmech.2020.112198
Curreli F, Ahmed S, Benedict Victor SM, Iusupov IR, Belov DS et al (2020) Preclinical optimization of gp120 entry antagonists as anti-hiv-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation. J Med Chem 63:1724–1749. https://doi.org/10.1021/acs.jmedchem.9b02149
Hawerkamp HC, Domdey A, Radau L, Sewerin P, Olah P et al (2021) Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation. Arthritis Res Ther 23:144. https://doi.org/10.1186/s13075-021-02509-8
Sengupta D, Timilsina U, Mazumder ZH, Mukherjee A, Ghimire D et al (2019) Dual activity of amphiphilic Zn(II) nitroporphyrin derivatives as HIV-1 entry inhibitors and in cancer photodynamic therapy. Eur J Med Chem 174:66–75. https://doi.org/10.1016/j.ejmech.2019.04.051
Liu T, Dai C, Sang H, Chen F, Huang Y et al (2020) Discovery of dihydropyrrolidones as novel inhibitors against influenza a virus. Eur J Med Chem 199:112334. https://doi.org/10.1016/j.ejmech.2020.112334
Lanave G, Lucente MS, Siciliano P, Zizzadoro C, Trerotoli P et al (2019) Antiviral activity of PHA767491 on Caprine alpha herpesvirus 1 in vitro. Res Vet Sci 126:113–117. https://doi.org/10.1016/j.rvsc.2019.08.019
Yao C, Zou Z, Zhang Y, Li J, Cheng F et al (2019) New adenine analogues and a pyrrole alkaloid from Selaginella delicatula. Nat Prod Res 33:1985. https://doi.org/10.1080/14786419.2018.1482892
Liu Z, Xia S, Wang X, Lan Q, Li P et al (2020) Sodium copper chlorophyllin is highly effective against enterovirus (ev) a71 infection by blocking its entry into the host cell. ACS Infect Dis 6:882–890. https://doi.org/10.1021/acsinfecdis.0c00096
Mohamed MS, Sayed AI, Khedr MA, Nofal S, Soror SH (2019) Evaluation of novel pyrrolopyrimidine derivatives as antiviral against gastroenteric viral infections. Eur J Pharm Sci 127:102–114. https://doi.org/10.1016/j.ejps.2018.10.022
Ianevski A, Yao R, Fenstad MH, Biza S, Zusinaite E et al (2020) Potential antiviral options against SARS-CoV-2 infection. Viruses 12:642. https://doi.org/10.3390/v12060642
Rao P, Shukla A, Parmar P, Rawal RM, Patel B et al (2020) Reckoning a fungal metabolite, pyranonigrin a as a potential main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation. Biophys Chem 264:106425. https://doi.org/10.1016/j.bpc.2020.106425
Lu S, Pan X, Chen D, Xie X, Wu Y (2021) Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses. Bioorg Chem 107:104619. https://doi.org/10.1016/j.bioorg.2020.104619
Fakhar Z, Khan S, AlOmar SY, Alkhuriji A, Ahmad A (2021) ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19. Sci Rep 11:234. https://doi.org/10.1038/s41598-020-79918-3
Varghese FS, van Woudenbergh E, Overheul GJ, Eleveld MJ, Kurver L et al (2021) Berberine and obatoclax inhibit SARS-Cov-2 replication in primary human nasal epithelial cells in vitro. Viruses 13:282. https://doi.org/10.3390/v13020282
Pecora F, Dal Canto G, Veronese P, Esposito S (2021) Treatment of multidrug-resistant and extensively drug-resistant tuberculosis in children: the role of bedaquiline and delamanid. Microorganisms 9:1074. https://doi.org/10.3390/microorganisms9051074
Sileshi T, Tadesse E, Makonnen E, Aklillu E (2021) The impact of first-line anti-tubercular drugs’ pharmacokinetics on treatment outcome: a systematic review. Clin Pharmacol 13:1–12. https://doi.org/10.2147/CPAA.S289714
Rossi I, Bettini R, Buttini F (2021) Resistant tuberculosis: the latest advancements of second-line antibiotic inhalation products. Curr Pharm Des 27:1436–1452. https://doi.org/10.2174/1381612827666210122143214
Seddon JA, Johnson S, Palmer M, van der Zalm MM, Lopez-Varela E et al (2021) Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment. Expert Rev Respir Med 15:221–237. https://doi.org/10.1080/17476348.2021.1828069.E
Guo H, Courbon GM, Bueler SA, Mai J, Liu J et al (2021) Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline. Nature 589:143–147. https://doi.org/10.1038/s41586-020-3004-3
Volynets GP, Tukalo MA, Bdzhola VG, Derkach NM, Gumeniuk MI et al (2020) Novel isoniazid derivative as promising antituberculosis agent. Future Microbiol 15:869–879. https://doi.org/10.2217/fmb-2019-0085
Shiva Raju K, AnkiReddy S, Sabitha G, Siva Krishna V, Sriram D et al (2019) Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents. Bioorg Med Chem Lett 29:284–290. https://doi.org/10.1016/j.bmcl.2018.11.036
Liu P, Yang Y, Ju Y, Tang Y, Sang Z et al (2018) Design, synthesis and biological evaluation of novel pyrrole derivatives as potential ClpP1P2 inhibitor against Mycobacterium tuberculosis. Bioorg Chem 80:422–432. https://doi.org/10.1016/j.bioorg.2018.06.004
Goudgaon NM, Basha NJ, Patil SB (2009) Synthesis and antimicrobial evaluation of 5- iodopyrimidine analogs. Indian J Pharm Sci 71:672. https://doi.org/10.4103/0250-474X.59551
Basha NJ, Upendar Reddy CH, Goudgaon NM (2008) Cyclization of 4-(2- minoanilino)-2-benzylthiopyrimidine to novel 1-(2-benzylthiopyrimidin-4-yi)-2-substituted benzimidazoles. Heterocycl Commun 14:469–472. https://doi.org/10.1515/HC.2008.14.6.469
Fathi P, Pan D (2020) Current trends in pyrrole and porphyrin-derived nanoscale materials for biomedical applications. Nanomedicine 15:2493–2515. https://doi.org/10.2217/nnm-2020-0125
Joshi SD, Dixit SR, Basha J, Kulkarni VH, Aminabhavi TM et al (2018) Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis. Bioorg Chem 81:440–453. https://doi.org/10.1016/j.bioorg.2018.08.035
Poce G, Cocozza M, Alfonso S, Consalvi S, Venditti G et al (2018) In vivo potent BM635 analogue with improved drug-like properties. Eur J Med Chem 145:539–550. https://doi.org/10.1016/j.ejmech.2017.12.075
Arumugam N, Almansour AI, Kumar RS, Krishna VS, Sriram D et al (2021) Stereoselective synthesis and discovery of novel spirooxindolopyrrolidine engrafted indandione heterocyclic hybrids as antimycobacterial agents. Bioorg Chem 110:104798. https://doi.org/10.1016/j.bioorg.2021.104798
Eng WS, Rejman D, Pohl R, West NP, Woods K et al (2018) Pyrrolidine nucleoside bisphosphonates as antituberculosis agents targeting hypoxanthine-guanine phosphoribosyltransferase. Euro J Med Chem 159:10–22. https://doi.org/10.1016/j.ejmech.2018.09.039
Krause M, Foks H, Ziembicka D, Augustynowicz-Kopeć E, Głogowska A et al (2020) 4-Substituted picolinohydrazonamides as a new class of potential antitubercular agents. Euro J Med Chem. https://doi.org/10.1016/j.ejmech.2020.112106
Li Petri G, Raimondi MV, Spano V, Holl R, Barraja P et al (2021) Pyrrolidine in drug discovery: a versatile scaffold for novel biologically active compounds. Top Curr Chem (Cham) 379:34. https://doi.org/10.1007/s41061-021-00347-5
Vitaku E, Smith DT, Njardarson JT (2014) Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals. J Med Chem 57:10257–10274. https://doi.org/10.1021/jm501100b
Acknowledgements
Authors are thankful to Dr. N.M. Goudgaon, professor (RTD), Department of Chemistry, Gulbarga University, Gulbarga, Karnataka, India, for his constant encouragement. Authors are also thankful to management of the college for providing necessary facility for the completion of this review article.
Author information
Authors and Affiliations
Contributions
Jeelan basha N involved in conceptualization, methodology, software, data curation, writing—original draft preparation, writing—reviewing and editing, supervision. Basavarajaiah SM took part in writing—reviewing and editing, methodology, and software. Shyamsunder K involved in methodology and software.
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jeelan Basha, N., Basavarajaiah, S.M. & Shyamsunder, K. Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Mol Divers 26, 2915–2937 (2022). https://doi.org/10.1007/s11030-022-10387-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11030-022-10387-8